About this trial
This study aims to develop an ultrasound image-based deep learning system to enable automatic segmentation, T-staging, and pathological grading prediction of bladder tumors. It seeks to enhance the objectivity, accuracy, and efficiency of bladder cancer diagnosis, reduce reliance on physician experience, and provide support for precision medicine and resource optimization.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
None
Disqualifiers
Age >85 years;
Patients unable to undergo abdominal/transrectal ultrasound (e.g., uncooperative individuals, technically inadequate images);
History of bladder tumor surgery, radiotherapy, chemotherapy, or systemic therapy within 3 months; ④ Patients with indwelling medical devices (e.g., double-J ureteral stents, urinary catheters);
Failure to undergo bladder tumor surgery within 2 weeks post-ultrasound; ⑥ Non-urothelial carcinoma or pathologically unconfirmed diagnoses.
Trial population
This study consecutively enrolled patients with suspected bladder tumors prospectively registered at the Department of Urology, Peking University First Hospital and Shanxi Province Cancer Hospital between May 2025 and May 2027.
Trial design
Cohort
Other
Treatments tested in this trial
observational diagnostic model development
Other interventionobservational diagnostic model development
Treatment groups
Trial outcomes
Primary outcomes
Overall Diagnostic Accuracy
Sponsors and contacts
Click on the lead sponsor to view all of their trials.